Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
10.1136/jitc-2022-004984
June 24, 2022
Clinical/Translational Cancer Immunotherapy
Section Edited by Douglas G. McNeel, MD, PhD; Claudia Palena, PhD; and Jeffrey S. Weber, MD, PhD
First-in-man clinical trials (prospective clinical data only); phase II/III clinical studies; immune monitoring investigations; tumor microenvironment; combination therapies; and cell therapies.
Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis
10.1136/jitc-2021-004381
June 23, 2022
Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress
10.1136/jitc-2021-004458
June 23, 2022
Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
10.1136/jitc-2022-004779
June 23, 2022
The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer
10.1136/jitc-2021-004312
June 22, 2022
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies
10.1136/jitc-2022-004766
June 22, 2022
L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression
10.1136/jitc-2021-003957
June 21, 2022
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
10.1136/jitc-2021-004226
June 21, 2022
Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186
10.1136/jitc-2021-004336
June 21, 2022
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
10.1136/jitc-2022-004495
June 18, 2022